Sequoia Capital

23andMe closes out 2020 with $82.5M in funding

  • by

DNA testing company 23andMe raised $82.5 million in funding, according to a recent filing. Earlier this year, decreased sales of tests kits led to cuts at the company and its competitors.

INVEST Precision Medicine Pitch Perfect winner spotlight: TrialSpark

  • by

Judges picked TrialSpark as the winner on the life sciences track of the pitch competition at MedCity’s virtual precision medicine conference. While the company is focused on improving clinical trials for others, it hopes eventually to bring drugs of its own to market.